The Greater Cannabis Company, Inc. reports unaudited results for the quarter ended March 31, 2026, with no revenue and a net loss of $33,376. Operating expenses fell to $33,376 from $43,536 a year earlier, mainly from lower stock-based and other operating costs.
Cash was only $1,439 against current liabilities of $776,464, resulting in a stockholders’ deficit of $775,025. Management explicitly concludes there is substantial doubt about the company’s ability to continue as a going concern through March 2027 without new funding.
The company continues to pursue development of a cannabinoid therapeutic licensed from Shaare Zedek Scientific Ltd., with Phase II clinical work dependent on securing specialized API and additional capital. A 1-for-1,500 reverse stock split and creation of super-voting Series B preferred shares have centralized voting control while leaving 944,935 common shares outstanding as of May 6, 2026.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.